The effectiveness of the antiviral agent ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl]guanine) against guinea pig cytomegalovirus was tested in vitro in guinea pig embryonic fibroblasts and in vivo in an experimental guinea pig cytomegalovirus labyrinthitis model. In vitro, ganciclovir completely prevented guinea pig cytomegalovirus infection of guinea pig embryonic fibroblasts at concentrations above 32.6 ,ug/ml. In vivo, antibody-negative animals had an average 17-dB elevation in their auditory nerve compound action potential thresholds (P < 0.01, t test) and showed signs bilaterally of guinea pig cytomegalovirus labyrinthitis 8 days after intrathecal inoculation of virus. Ganciclovir administration starting 1 day before inoculation prevented the development of both cochlear histopathologic change and hearing loss. Guinea pig cytomegalovirus meningitis was observed in both the drug-treated and untreated groups. High-pressure liquid chromatography confirmed the presence of ganciclovir in the serum, perilymph, and cerebrospinal fluid of the drug recipients. Prophylactic ganciclovir thus can protect the cochlea from the histopathologic changes and hearing loss normally associated with experimental guinea pig cytomegalovirus labyrinthitis.
intrathecal inoculation of virus. Ganciclovir administration starting 1 day before inoculation prevented the development of both cochlear histopathologic change and hearing loss. Guinea pig cytomegalovirus meningitis was observed in both the drug-treated and untreated groups. High-pressure liquid chromatography confirmed the presence of ganciclovir in the serum, perilymph, and cerebrospinal fluid of the drug recipients. Prophylactic ganciclovir thus can protect the cochlea from the histopathologic changes and hearing loss normally associated with experimental guinea pig cytomegalovirus labyrinthitis.
Cytomegalovirus (CMV) is the leading infectious cause of congenital sensorineural hearing loss in humans. As many as 2.5% of all newborns have been estimated to be congenitally infected with CMV (10, 11, 13, 25, 26) . About 5% of congenitally infected infants develop symptomatic congenital CMV syndrome. One half of these infants die, and the survivors typically exhibit significant and permanent intellectual, auditory, visual, or neurologic sequellae of their infection (26) . Ninety-five percent of infants congenitally infected with CMV are asymptomatic at birth. However, as many as 20% of infants who appear normal at birth are later found to have sensorineural deafness, neurologic abnormalities, or mental retardation (11, 18) . Recent epidemiological studies have concluded that in the United States alone both congenital CMV infections and primary CMV infections later in life may account for as many as 40,000 new cases of sensorineural hearing loss per year (6) . CMV may also be a significant factor in the sensorineural hearing loss and central auditory dysfunction found in up to 68% of patients with acquired immunodeficiency syndrome (J. Gardi, C. D. Sooy, D. Morledge, P. Chambers, R. Gorter, and I. Medina, Assoc. Res. Otolaryngol. 10:93, 1987) , over 90% of whom are infected with CMV (20) . The pathogenesis of CMVinduced sensorineural hearing loss is poorly understood, and there is no known effective treatment.
The species specificity of CMV has prevented the development of animal models using human CMV. However, it was recently demonstrated that the virology and histopathology of guinea pig CMV (GPCMV) closely resemble those of human CMV disease (2, 27) . Using GPCMV, we established a model of virus labyrinthitis in guinea pigs after inoculation of seronegative animals with GPCMV via intracochlear or intrathecal routes (12, 29, 30 Having established the dose-response kinetics of GPCMV labyrinthitis, it is possible to use this model to evaluate the efficacy of the antiviral agent ganciclovir, also called DHPG. Ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl]guanine) is an acyclic nucleoside which has been shown to inhibit CMV replication in humans (14, 15, 17, 24) and other mammals, including guinea pigs (8, 9, 23) . This study was designed to determine whether prophylactic ganciclovir could prevent the labyrinthitis and hearing loss normally associated with intrathecal inoculation of 1032 TCID50 of GPCMV into seronegative animals. The treatment protocol used was chosen to optimize the potential effectiveness of the drug. TCID50ml were stored in 150-,ul aliquots at -70°C until needed.
MATERIALS AND METHODS

Animals
(ii) Inactivated virus. GPCMV stock solution was inactivated by being mixed with 4' aminomethyl-4,5',8-trimethyl psoralen (10 ,ug/ml) (Calbiochem-Behring, La Jolla, Calif.) followed by a 10-min exposure to long-wavelength UV light (19) . The inactivated virus stock was then divided into aliquots and frozen at -70°C until needed.
Enzyme immunoassay for antibodies to GPCMV. The assay of antibody in microliter quantities of serum and perilymph was performed by using an enzyme immunoassay with a filtration system originally described by Cleveland et al. (3) and described in detail for GPCMV elsewhere (12) .
CM and auditory nerve compound AP recordings. CM and auditory nerve compound AP are electrophysiological measures of the functional integrity of the inner ear sensory cells and auditory (eighth cranial) nerve, respectively (5). The surgical and electrophysiological recording procedures were detailed previously (30) . Briefly, the external ear was left intact, and a small opening was made in the inferior-posterior and tympanic chambers of the bulla to provide access to the cochlear round window. A silver ball recording electrode was placed adjacent to the round window membrane, and a reference electrode was placed in contact with the dorsal neck muscles. CM and AP were amplified 1,000 times and filtered at 0.10 to 30 kHz. CM and AP were measured with a Hewlett-Packard 3561A Signal Analyzer.
Calibrated auditory stimuli were delivered to the bony external meatus through a closed acoustic system (30) . Stimuli were tones presented continuously for CM or gated (6 kHz, 30-ms duration, 3/s, 1-ms rise/fall time) for AP recordings. All recordings were conducted inside a doublewalled International Acoustics Co. sound-attenuated chamber.
Sampling and inoculation techniques. For sampling of cerebrospinal fluid (CSF), an incision was made in the neck and the muscles were blunt dissected down to the dura at the level of the foramen magnum. The dura was cleaned of all traces of blood. A clear blood-free CSF sample was obtained by inserting a glass micropipette through the dura into the cisterna magna. When necessary, live or inactivated virus inoculations were done after CSF sampling by inserting another glass micropipette, attached to a 100-,lI Hamilton syringe with a repeating dispenser, through the dura and injecting 50 ,ul of the appropriate suspension into the cisterna magna. After the inoculation micropipette was removed, the small hole in the dura was teased closed and the area was sealed with Gelfoam. For sampling of perilymph, a small hole, 250 ,um in diameter, was hand drilled into the basal turn scala tympani, and approximately 25 TCID50 of GPCMV that had been inactivated in 50 ,ul (inactivated virus control); (ii) a live virus group (n = 7) which was inoculated intrathecally with 103.2 TCID50 of GPCMV in 50 ptl (infected-untreated group); and (iii) a prophylactic drug group (n = 6) which, in addition to intrathecal inoculation with live GPCMV, also received 100 mg of ganciclovir per kg twice a day intraperitoneally starting 1 day before virus injection and continuing throughout the 8 days of infection (infected-ganciclovir group). On day 0, before intrathecal inoculation, the base-line CM and AP thresholds were determined for each animal, and serum and CSF samples were taken. On day 8, the terminal day, CM and AP thresholds were remeasured; serum, right and left perilymph, and CSF samples were taken; and then each guinea pig was fixed by cardiac perfusion with warm saline and 5% paraformaldehyde. Brains and cochleas were processed in paraffin for histopathologic evaluation. RESULTS Activity of ganciclovir against GPCMV in cell culture. The activity of ganciclovir against GPCMV replication in GPE fibroblasts was assessed in vitro. In comparison to drug-free, virus-infected controls, ganciclovir inhibited replication of GPCMV in GPE fibroblasts at drug concentrations above 16.3 ,ug/ml and completely inhibited GPCMV replication at concentrations above 32.6 p,g/ml. Ganciclovir did not inhibit GPE fibroblast proliferation even at 261.1 jig/ml, the highest concentration used.
Pharmacokinetics of ganciclovir. The pharmacokinetics of ganciclovir were examined in two guinea pigs (Fig. 1) (Fig. 2B and 3B) . A small number of lymphocytes and plasma cells were occasionally seen in the scala tympani of the extreme basal turn. There was no evidence of labyrinthitis. The perivascular spaces within the modiolus were clear and free of lymphocytic infiltration.
The infected-untreated group ( Fig. 2A and 3A ) uniformly showed evidence of acute labyrinthitis in the basal turn at 8 days after GPCMV inoculation. The scalae tympani in these guinea pigs showed numerous inflammatory cells, extensive Comparison of the auditory nerve compound AP thresholds (mean plus one standard deviation) for the three experimental groups on days 0 and 8. The infected-untreated group (CMV; n = 14 ears) showed a significant threshold elevation on day 8, while AP threshold shifts for the control (n = 10 ears) and infected-ganciclovir (CMV +Ganciclovir; n = 12 ears) groups were not significant. SPL, Sound pressure level re. 0.0002 dynes/cm2. perilabyrinthine fibrosis, and hemorrhage. However, the organ of Corti, the region where the sensory hair cells are located, showed good preservation. Within the modiolus, the regions around the perivascular blood vessels showed extensive lymphocytic infiltration. These perivascular spaces, which were normally seen as clear regions around the blood vessels in inactivated virus control and infectedganciclovir group animals, were completely filled with lymphocytes, macrophages, and plasma cells for animals in the infected-untreated group (Fig. 2A) .
(ii) Brains. The brains of guinea pigs in the inactivated virus control group showed normal morphology. In contrast, all of the animals in the infected-ganciclovir and infecteduntreated groups exhibited meningitis. The histopathology consisted primarily of swelling of the meninges; inflammatory infiltration with lymphocytes, plasma cells, and macrophages; and the presence of a subarachnoid fibroid matrix. None of the intrathecally inoculated guinea pigs had any evidence of GPCMV encephalitis.
Cochlear pathophysiology. (i) Auditory nerve compound AP thresholds. The AP thresholds for all subjects were measured on day 0, before the intrathecal inoculation, and again on day 8. Only the infected-untreated group showed a significant elevation in AP thresholds after infection (Fig. 4) . Mean AP for this group was increased 17 dB (P < 0.01, paired-sample t test), indicating that auditory nerve function was impaired (5) . AP thresholds for the inactivated virus control (P > 0.50) and infected-ganciclovir (P > 0.20) groups did not change significantly between days 0 and 8 (paired-sample t tests).
(ii) CM responses. The CM thresholds for all guinea pigs were also determined on day 0, before intrathecal inoculation, and again on day 8. The average CM threshold for each of the three groups did not change significantly (P > 0.10, two-way analyses of variance) between days 0 and 8 (Fig. 5) , indicating no significant impairment of cochlear outer hair cell function (5).
DISCUSSION
Ganciclovir is being used to treat immunosuppressed patients with serious CMV infections. The most extensive experience has been with patients with acquired immunodeficiency syndrome who have CMV retinitis. Ganciclovir promotes healing of retinal lesions with resolution of viremia (1, 7, 22) . The only serious adverse effects associated with ganciclovir treatment have been neutropenia and possible sterility, which are dose related and reversible (4) .
The present study evaluated the antiviral activities of ganciclovir against GPCMV in vitro and in vivo. In vitro, ganciclovir was not toxic to GPE cell lines at even the highest concentrations tested (261.1 Fxg/ml), levels significantly above human therapeutic levels. Ganciclovir was observed to inhibit replication of GPCMV in GPE fibroblasts at concentrations of 16.3 ,Lg/ml, consistent with the data of Fong et al. (8) , who estimated the 50% effective dose of the drug against GPCMV in cell cultures to be 18.1 ,ug/ml. As pointed out by Fong et al. (8) , the 50% effective dose in guinea pig cell lines is significantly higher than the 50% effective dose for human fibroblasts, which ranges from 0.04 to 3.3 ,ug/ml (9, 16, 28) .
In studies with guinea pigs, Fong et al. (8) found that ganciclovir therapy was effective in modifying histopathologic lesions in the kidney and salivary gland but not in the spleen, liver, or lung. In our experimental model, ganciclovir provided significant protection for the cochlea against GPCMV-induced anatomical and functional pathology. Infected-ganciclovir group animals had normal cochlear morphologies and hearing thresholds 8 days after infection; however, a small number of lymphocytes were occasionally observed floating freely in the scala tympani of the cochlear basal turn of these animals. The source of these lymphocytes was presumably the CSF via the cochlear aqueduct, since all of the infected-ganciclovir group animals had documented GPCMV meningitis.
With the GPCMV dose and infection period used, the pathophysiology in the cochlea was confined to AP changes, while CM thresholds were not affected, consistent with our previous observations (Woolf et Although we have demonstrated that ganciclovir can be an effective agent for the prevention of acute GPCMV labyrinthitis, we do not yet know whether ganciclovir permanently prevents GPCMV labyrinthitis or only suppresses the infection for the duration of drug therapy. This is particularly relevant since in studies of patients without the benefit of effective immunity, such as patients with acquired immunodeficiency syndrome, it has been found that ganciclovir suppresses CMV retinitis for the duration of therapy but that the retinitis usually returns if the drug is withdrawn (14, 15 
